2024-05-12-艾昆纬-艾昆纬年议长局基准报告（英）_19页_1mb

报告摘要

2024 Speaker Bureau Benchmarks Report Summary

Overview

The 2023 Speaker Bureau report highlights a significant shift in life sciences events post-COVID-19, with virtual events normalizing and accounting for 50% of program volume, up from a steady growth that began in 2022. Overall event volume increased by approximately 18% from 2022, driven by companies leveraging virtual options to address resource constraints and market disruptions. Live events still dominate but are declining in share, while virtual formats like webinars offer broader reach and cost efficiency.

Key Findings

Program Mix: Virtual programs (including Host and Link types) rose to 50% of total events in 2023, with a shift away from pure live events. Virtual Link programs, in particular, experienced substantial growth, aided by their ease of deployment and suitability for market-driven webinars.
Attendance Trends: Average HCP attendance at Live events remained steady, while Virtual attendance continues to increase, reaching record highs. Therapeutic areas like oncology showed the highest attendance, partly due to regional preferences and the format's ability to handle larger audiences. Neurology attendance declined, indicating evolving priorities.
Cost Analysis: Costs per program and per attendee increased due to inflation, with Live Out-of-Office programs seeing the steepest rise. Despite higher expenses, Virtual events remain cost-effective, allowing for better ROI through wider accessibility.
Therapeutic Area Variations: Different specialties exhibit divergent trends; for example, cardiovascular/metabolic and oncology saw increases in Virtual programs, while infectious disease/immunology experienced shifts in attendance and program types. Speaker fees vary by therapeutic area, with oncology commanding higher rates for national experts.

Conclusion

Speaker bureau programs continue to strengthen, with a balanced approach recommended for 2024. Companies should optimize the mix of Live and Virtual events to align with HCP preferences, budget constraints, and therapeutic-area needs. The channel's adaptability supports industry growth, and data-driven insights can enhance strategy and compliance.